Øystein Rekdal, CEO in Lytix Biopharma, presented at Redeye Life Science Day 2023 in Stockholm – 23rd of November

Redeye interviewed Øystein Rekdal about Lytix and his role as CEO

The positive interim Phase II data with LTX-315 from Verrica Pharmaceuticals Inc. (Lytix Biopharma’s licensing partner) stirs attention

Redeye initiates coverage of Lytix Biopharma

Lytix Biopharma’s innovative and unique solution emphasized in national clinical research report